Tissue accumulation of metabolites during chronic administration of piperazine-substituted phenothiazine drugs.
D000588:Amines / Q000378:metabolism; D000818:Animals; D014150:Antipsychotic Agents / Q000378:metabolism*; D001921:Brain / Q000378:metabolism; D002855:Chromatography, Thin Layer; D003640:Dealkylation; D005029:Ethylenediamines / Q000378:metabolism / Q000652:urine; D005260:Female; D005476:Fluphenazine / Q000378:metabolism / Q000627:therapeutic use / Q000652:urine; D006801:Humans; D007668:Kidney / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008297:Male; D013058:Mass Spectrometry; D001523:Mental Disorders / Q000188:drug therapy; D010546:Perphenazine / Q000378:metabolism / Q000652:urine; D010879:Piperazines / Q000378:metabolism*; D011346:Prochlorperazine / Q000378:metabolism / Q000652:urine; D013045:Species Specificity; D013454:Sulfoxides / Q000378:metabolism; D013997:Time Factors; D014268:Trifluoperazine / Q000378:metabolism / Q000652:urine
D000588:Amines; D014150:Antipsychotic Agents; D005029:Ethylenediamines; D010879:Piperazines; D013454:Sulfoxides; D014268:Trifluoperazine; D010546:Perphenazine; D005476:Fluphenazine; D011346:Prochlorperazine